Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 98

recruiting
3 987
countries
28
conditions
2 109

1 221 trials match your criteria

Oesophageal carcinoma

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Endometrial cancer

Not recruiting

Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GEN1046

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Breast cancer

Not recruiting

Study on the Safety and Antitumor Activity of ARV-471 and Ribociclib in Adults with ER+ Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib

Autism spectrum disorder

Not recruiting

Study on the Effects of Pitolisant for Children and Adolescents with Autism Spectrum Disorder

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Pitolisant

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.